TY - JOUR AU - GANDRA, SMITHA PY - 2020/11/15 Y2 - 2024/03/29 TI - FORMULATION AND EVALUATION OF OPTIMISED MALTODEXTRIN BASED PRONIOSOME POWDERS CONTAINING BAZEDOXIFENE ACETATE FOR ORAL DELIVERY JF - International Journal of Current Pharmaceutical Research JA - Int J Curr Pharm Sci VL - 12 IS - 6 SE - Original Article(s) DO - 10.22159/ijcpr.2020v12i6.40285 UR - https://journals.innovareacademics.in/index.php/ijcpr/article/view/40285 SP - 56-66 AB - <p><strong>Objective: </strong>The main objective of the present study was to develop proniosomal formulations to enhance the oral bioavailability of bazedoxifene acetate by improving solubility, dissolution and/or intestinal permeability.</p><p><strong>Methods: </strong>Proniosomal powder formulations were prepared with bazedoxifene acetate drug varying the span 40 and cholesterol ratio in the range of 0.8:0.2 to 0.2:0.8 using maltodextrin as a carrier by slurry method. The prepared proniosomal powder was filled into capsules. The bioavailability enhancement of proniosomes loaded with drug was studied focusing on non-ionic surfactants composition and drug: span 40 ratio. Prepared proniosomes were characterized for their particle size distribution, zeta potential, entrapment efficiency, <em>in vitro</em> dissolution study and thermal characteristics to understand the phase transition behavior. Further, the formulated proniosomes were subjected to stability behavior, <em>ex vivo</em> permeation studies using rat intestine followed by <em>in vivo</em> studies.</p><p><strong>Results: </strong>Physico-chemical studies help in the optimization of formulations. Enhancement in dissolution is due to the incorporation of bazedoxifene acetate into the non-ionic surfactant and change in the physical state from crystalline to amorphous, thus improving oral bioavailability. <em>Ex</em> <em>vivo </em>studies show significant permeation enhancement across the gastrointestinal membrane compared to control.</p><p><strong>Conclusion: </strong>In conclusion, proniosomes provide a powerful and functional way of the distribution of inadequately soluble bazedoxifene acetate drug, which is proved from <em>in vivo</em> studies based on the enhanced oral delivery.</p> ER -